<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404244</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU P25a/ 2020</org_study_id>
    <nct_id>NCT04404244</nct_id>
  </id_info>
  <brief_title>Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic</brief_title>
  <acronym>PedCan-COVID</acronym>
  <official_title>Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatma Soliman Elsayed Ebeid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective follow-up non-intervention study that will be carried out at
      Hematology/ Oncology Department, Children's hospital, Ain-Shams University, Cairo, Egypt. All
      followed-up children below 18 years with cancer during the one year study period from May
      2020 till Apr 2021 either at the out-patients clinic or inpatient department will be
      recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Procedures:

      On admission or during the outpatient visit:

        1. Obtaining an informed consent .

        2. Full medical history, concurrent medications, demographic data and epidemiological data
           (history of contact to a COVID-19 case, history of travel), will be obtained.

        3. A thorough physical examination will be performed.

        4. Body weight, height, BMI, vital signs (blood pressure, heart rate and temperature) and
           blood oxygen saturation) will be recorded.

        5. Laboratory to perform the following tests:

      Complete blood count with differential counts, COVID -19 reverse Transcription Polymerase
      Chain Reaction (RT-PCR) test by nasopharyngeal swab.

      During admission:

      Whenever unexplained fever and or respiratory symptoms developed or whenever COVID19
      suspected to have the following to be performed:

        1. Symptom developed that necessitates to repeat oropharyngeal and nasopharyngeal swab if
           indicated will be collected

        2. Chest X-ray or CT chest will be recorded.

        3. Laboratory to perform the following tests:

      Complete blood count with differential counts,

      COVID-19 RT-PCR test by oropharyngeal and nasopharyngeal swab:

      C-reactive protein and serum ferritin level. Coagulation test; D. dimer, prothrombin time and
      INR. Routine bacteriological study, blood culture and other symptoms/signs based cultures
      will be recorded

      On discharge:

        -  Date of discharge

        -  Period of admission

        -  Period of fever

        -  A thorough physical examination will be performed

        -  Record the outcome
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 among children with cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Measure the incidence of COVID-19 infection among children with cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Families training</measure>
    <time_frame>12 months</time_frame>
    <description>Families training about adhering to standard precautions for basic and respiratory hygiene to reduce the risk of transmission</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronavirus COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All followed-up children below 18 years with with malignancy either hematological or solid
        tumors or hematological condition during the one year study period from May 2020 till Apr
        2021 either at the out-patients clinic or inpatient department will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children below 18 years with malignancy either hematological or solid tumors or

          2. Children below 18 years with hematological condition

        Exclusion Criteria:

        1. Patients or care-givers refusal to be enrolled in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatma Ebeid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excuitive Director of MARSI-CRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma Ebeid</last_name>
    <phone>+201095569596</phone>
    <email>dr.fatma_ebeid@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center</name>
      <address>
        <city>Cairo</city>
        <state>Non-US</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Soliman E Ebeid</last_name>
      <phone>01095569596</phone>
      <email>dr.fatma_ebeid@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Fatma Soliman Elsayed Ebeid</investigator_full_name>
    <investigator_title>Executive Director of Faculty of Medicine Ain Shams University Research Institute - Clinical Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

